NCT01671332 2020-05-12
Docetaxel +/- Suramin in 2nd Line Advanced Non-Small Cell Lung Cancer
University of Wisconsin, Madison
Phase 2 Completed
Clinical Trials
11 trialsNCT00083109 2015-05-25
Fluorouracil and Low-Dose Suramin as Chemosensitization in Treating Patients With Metastatic Renal Cell (Kidney) Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00054028 2015-03-17
Suramin and Paclitaxel in Treating Women With Stage IIIB-IV Breast Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00006476 2013-06-26
Suramin in Treating Patients With Recurrent Bladder Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00066768 2013-06-04
Suramin and Either Docetaxel or Gemcitabine in Treating Patients With Stage IIIB or Stage IV Platinum-Refractory Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00002723 2013-02-28
Low, Intermediate, or High Dose Suramin in Treating Patients With Hormone-Refractory Prostate Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00004073 2012-05-03
Suramin Plus Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT00003038 2011-08-03
Combination Chemotherapy With Suramin Plus Doxorubicin in Treating Patients With Advanced Solid Tumors
Mayo Clinic
Phase 1 Completed
NCT00002881 2010-11-09
Flutamide, Suramin, and Hydrocortisone in Treating Patients With Prostate Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00001266 2008-03-04
A Phase II Trial of Leuprolide + Flutamide + Suramin in Untreated Poor Prognosis Prostate Carcinoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00001381 2008-03-04
A Phase I Trial Using Suramin to Treat Superficial Transitional Cell Carcinoma of the Bladder
National Institutes of Health Clinical Center (CC)
Phase 1 Completed